Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy
https://pixabay.com/en/doctor-blood-life-veins-pain-2346235/

Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy

In the average person, you would expect to see normal to near-optimal low-density lipoprotein (LDL) cholesterol levels sitting at 129 mg/DL or lower; levels under 100 are seen as healthier.…

Continue Reading Adding Evinacumab to Care Plan Can Significantly Increase HoFH Life Expectancy
BLA for Evinacumab, a Treatment for HoFH, Receives Priority Review Status
source: pixabay.com

BLA for Evinacumab, a Treatment for HoFH, Receives Priority Review Status

  This week, Regeneron Pharmaceuticals announced that their Biologics License Application (BLA) for evanicumab, a treatment for homozygous familial hypercholesterolemia (HoFH), was granted Priority Review status by the FDA. The…

Continue Reading BLA for Evinacumab, a Treatment for HoFH, Receives Priority Review Status